# Contact Legal Wolverine: Editorial Inquiries on the BPC-157 TB-500 Digest

> Contact Legal Wolverine with editorial questions or corrections about the BPC-157 TB-500 research and regulatory digest. Editorial inquiries only — not a clinic, not a vendor, not a prescriber.

Editorial questions, corrections, and sourcing notes about the BPC-157 TB-500 digest are welcome. This is an editorial desk, not a clinic and not a sales channel.

## Editorial inquiries only

Use the form to reach the editorial desk about the BPC-157 TB-500 digest. We read every message about a citation, a figure, a possible error, or a regulatory update we should reflect. If a study has been superseded, a DOI has moved, or the FDA record has changed, tell us and we will check it against the source.

What this desk is not: it is not a clinic, not a pharmacy, not a prescriber, and not a vendor. We cannot evaluate your health, recommend a dose, supply any peptide, or advise on obtaining the Wolverine blend. We do not provide medical or legal advice. Questions of that kind belong with an appropriately licensed professional, not with an editorial project.

## What to expect

We prioritize messages that improve the accuracy of the record: a miscited PMID, a number that does not match the source paper, a regulatory development we have not yet incorporated, or a place where the [Wolverine legal status and 503A compounding](/legal-status) page should be updated to reflect a new FDA action. Corrections grounded in a primary source are the fastest to act on.

We do not collect personal health information, and we ask that you do not send any. Keep inquiries to the editorial content itself — the studies, the citations, the regulatory status, and the way the blend's evidence is drawn on these pages. For the underlying sources, the [Wolverine blend references](/references) page lists everything cited, with DOIs and PubMed or FDA links, so a correction can be checked against the primary record before we change anything on the sheet.

---

The Wolverine blend read off a drafting table — BPC-157 and TB-500 set down as two dimensioned components, their measured findings inked solid and their unproven joint left dashed, with the FDA and WADA record kept in the title block and nothing here prescribed or sold.